Oncocyte Corp Files 8-K on Director Changes & Compensation
Ticker: IMDX · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1642380
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
TL;DR
Oncocyte Corp 8-K: Board shakeup and executive pay changes filed Oct 11.
AI Summary
On October 11, 2024, Oncocyte Corporation filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes information on matters submitted to a vote of security holders and financial statements. Specific details regarding the departures, elections, appointments, and compensatory arrangements are outlined within the report.
Why It Matters
This filing signals potential shifts in corporate governance and executive strategy at Oncocyte Corporation, which could impact investor confidence and future business direction.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate underlying strategic shifts or internal challenges within a company.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- October 11, 2024 (date) — Date of earliest event reported
FAQ
What specific changes were made to Oncocyte Corporation's board of directors?
The 8-K filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers', but the specific names and details of these changes are not provided in the excerpt.
Were there any changes to executive compensation arrangements?
Yes, the filing explicitly mentions 'Compensatory Arrangements of Certain Officers' as an item of information, suggesting that changes or updates to executive compensation were reported.
What other items were covered in this 8-K filing?
Besides director and officer changes and compensation, the filing also covers 'Submission of Matters to a Vote of Security Holders' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 11, 2024.
What is Oncocyte Corporation's Standard Industrial Classification?
Oncocyte Corporation's Standard Industrial Classification is 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]'.
Filing Stats: 1,085 words · 4 min read · ~4 pages · Grade level 14.3 · Accepted 2024-10-15 16:22:27
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex10-1.htm (EX-10.1) — 154KB
- 0001493152-24-041133.txt ( ) — 412KB
- ocx-20241011.xsd (EX-101.SCH) — 3KB
- ocx-20241011_lab.xml (EX-101.LAB) — 33KB
- ocx-20241011_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: October 15, 2024 By: /s/ Joshua Riggs Name: Joshua Riggs Title: President and Chief Executive Officer